Follow the people · Insider
Cintia Piccina
Cintia Piccina files insider transactions with the SEC as an u.s. cco & country gen manager of Autolus Therapeutics (AUTL). We hold 1 disclosed purchase or sale filed since 31 January 2022, 1 of them in the last 90 days.
- Files forAUTL
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure3 September 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 September 2026 — 2 September 2026U.S. CCO & Country Gen Manager · Autolus Therapeutics (AUTL)3 Form 4 lines · source: SEC Form 4
- Filed 31 January 2022 — 20 February 2025Chief Commercial Officer · Adaptimmune Therapeutics (ADAP)11 Form 4 lines · source: SEC Form 4
- Filed 3 July 2023 — 3 July 2023Chief Commercial Officer · Allovir (ALVR)2 Form 4 lines · source: SEC Form 4
- Filed 17 January 2023 — 17 January 2023Chief Commercial Officer · Adaptimmune Therapeutics (ADAP])3 Form 4 lines · source: SEC Form 4
Everything they disclosed
19 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 20,000 shares of Autolus TherapeuticsSEC Form 43 September 2026American Depositary Shares · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 6,713 shares of Autolus TherapeuticsSEC Form 43 September 2026American Depositary Shares · traded 2 September 2026 · filed 3 September 2026
- exercised options over 20,000 shares of Autolus Therapeutics (a derivative holding)SEC Form 43 September 2026Restricted Share Units · traded 1 September 2026 · filed 3 September 2026
- was granted 1,612,032 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 420 February 2025Option to purchase Ordinary Shares · traded 20 February 2025 · filed 20 February 2025
- was granted 1,074,696 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 420 February 2025Option to purchase Ordinary Shares · traded 20 February 2025 · filed 20 February 2025
- ▼ sold on the open market 12,991 shares of Adaptimmune TherapeuticsSEC Form 415 January 2025American Depositary Shares representing Ordinary Shares · traded 15 January 2025 · filed 15 January 2025
- ▼ sold on the open market 24,531 shares of Adaptimmune TherapeuticsSEC Form 418 June 2024American Depositary Shares representing Ordinary Shares · traded 18 June 2024 · filed 18 June 2024
- was granted 5,088,864 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 418 March 2024Option to purchase Ordinary Shares · traded 18 March 2024 · filed 18 March 2024
- was granted 1,130,832 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 418 March 2024Option to purchase Ordinary Shares · traded 18 March 2024 · filed 18 March 2024
- was granted 273,000 shares of Allovir (a derivative holding)SEC Form 45 July 2023Stock Option (Right to Buy) · traded 3 July 2023 · filed 5 July 2023
- was granted 147,000 shares of AllovirSEC Form 45 July 2023Common Stock · traded 3 July 2023 · filed 5 July 2023
- ▼ sold on the open market 11,890 shares of Adaptimmune TherapeuticsSEC Form 431 January 2023American Depositary Shares representing Ordinary Shares · traded 31 January 2023 · filed 31 January 2023
- was granted 1,407,072 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2023Option to purchase Ordinary Shares · traded 17 January 2023 · filed 17 January 2023
- was granted 314,256 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2023Option to purchase Ordinary Shares · traded 17 January 2023 · filed 17 January 2023
- was granted 181,560 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2023Option to purchase Ordinary Shares · traded 17 January 2023 · filed 17 January 2023
- ▼ sold on the open market 21,040 shares of Adaptimmune TherapeuticsSEC Form 41 August 2022American Depositary Shares representing Ordinary Shares · traded 1 August 2022 · filed 1 August 2022
- was granted 3,376,992 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 431 January 2022Option to purchase Ordinary Shares · traded 31 January 2022 · filed 31 January 2022
- was granted 754,200 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 431 January 2022Option to purchase Ordinary Shares · traded 31 January 2022 · filed 31 January 2022
- was granted 335,184 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 431 January 2022Option to purchase Ordinary Shares · traded 31 January 2022 · filed 31 January 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.